MX2021013014A - Compuestos que comprenden n-metil-2-piridona y sales farmaceuticamente aceptables. - Google Patents

Compuestos que comprenden n-metil-2-piridona y sales farmaceuticamente aceptables.

Info

Publication number
MX2021013014A
MX2021013014A MX2021013014A MX2021013014A MX2021013014A MX 2021013014 A MX2021013014 A MX 2021013014A MX 2021013014 A MX2021013014 A MX 2021013014A MX 2021013014 A MX2021013014 A MX 2021013014A MX 2021013014 A MX2021013014 A MX 2021013014A
Authority
MX
Mexico
Prior art keywords
compounds
pyridone
methyl
acceptable salts
pharmaceutically acceptable
Prior art date
Application number
MX2021013014A
Other languages
English (en)
Inventor
Mark Bell
Andrew Woodland
Original Assignee
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dundee filed Critical Univ Dundee
Publication of MX2021013014A publication Critical patent/MX2021013014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

La presente invención se refiere a compuestos que comprenden N-metil-2-piridona y sales farmacéuticamente aceptables y composiciones de tales compuestos. Tales compuestos son útiles en terapias antiinflamatorias y contra el cáncer. Por lo tanto, la presente invención también se refiere a tales compuestos para uso como medicamentos, particularmente para el tratamiento de enfermedades inflamatorias y en el campo de la oncología.
MX2021013014A 2019-04-24 2020-04-22 Compuestos que comprenden n-metil-2-piridona y sales farmaceuticamente aceptables. MX2021013014A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1905721.5A GB201905721D0 (en) 2019-04-24 2019-04-24 Compounds
PCT/EP2020/061173 WO2020216779A1 (en) 2019-04-24 2020-04-22 Compounds comprising n-methyl-2-pyridone, and pharmaceutically acceptable salts

Publications (1)

Publication Number Publication Date
MX2021013014A true MX2021013014A (es) 2022-01-18

Family

ID=66810205

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013014A MX2021013014A (es) 2019-04-24 2020-04-22 Compuestos que comprenden n-metil-2-piridona y sales farmaceuticamente aceptables.

Country Status (14)

Country Link
US (1) US20220204500A1 (es)
EP (1) EP3958976A1 (es)
JP (1) JP2022530405A (es)
KR (1) KR20220012250A (es)
CN (1) CN113924298A (es)
AU (1) AU2020263112A1 (es)
BR (1) BR112021021284A2 (es)
CA (1) CA3148317A1 (es)
EA (1) EA202192905A1 (es)
GB (2) GB201905721D0 (es)
IL (1) IL287470B1 (es)
MX (1) MX2021013014A (es)
WO (1) WO2020216779A1 (es)
ZA (1) ZA202109179B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
CN115667237A (zh) * 2020-07-17 2023-01-31 成都苑东生物制药股份有限公司 作为bet抑制剂的新型杂环化合物
GB202016977D0 (en) * 2020-10-26 2020-12-09 In4Derm Ltd Compounds
CN113582859A (zh) * 2021-06-28 2021-11-02 佳尔科生物科技南通有限公司 一种4-酚氧基-3-氨基苯甲醚的制备方法
EP4363417A1 (en) 2021-06-29 2024-05-08 Tay Therapeutics Limited Pyrrolopyridone derivatives useful in the treatment of cancer
CN115611890A (zh) * 2021-07-15 2023-01-17 成都苑东生物制药股份有限公司 一种新型噻吩类bet溴结构域抑制剂、其制备方法及医药用途
WO2023081720A1 (en) * 2021-11-03 2023-05-11 Vyne Therapeutics Inc. Uses of pan bet inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2563057T3 (es) 2009-11-05 2016-03-10 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiazepina
ME02356B (me) 2009-11-05 2016-06-20 Glaxosmithkline Llc Inhibitor bromodomena benzodiazepina
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2014125408A2 (en) * 2013-02-12 2014-08-21 Aurigene Discovery Technologies Limited Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
RU2016102647A (ru) 2013-06-28 2017-08-01 Эббви Инк. Ингибиторы бромодомена
US20150148372A1 (en) * 2013-11-26 2015-05-28 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015081280A1 (en) 2013-11-26 2015-06-04 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution
MA40940A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
EP3265453B1 (en) * 2015-03-05 2022-06-29 Boehringer Ingelheim International GmbH New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9
SG11201808003RA (en) * 2016-04-15 2018-10-30 Abbvie Inc Bromodomain inhibitors
WO2018130174A1 (zh) * 2017-01-11 2018-07-19 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
CN109384784B (zh) * 2017-08-10 2021-01-12 浙江海正药业股份有限公司 磺酰胺类衍生物、其制备方法及其在医药上的用途
CN109384785B (zh) * 2017-08-10 2021-09-28 浙江海正药业股份有限公司 吡咯并吡啶酮类衍生物、其制备方法及其在医药上的用途

Also Published As

Publication number Publication date
GB202116739D0 (en) 2022-01-05
ZA202109179B (en) 2023-10-25
CA3148317A1 (en) 2020-10-29
US20220204500A1 (en) 2022-06-30
EP3958976A1 (en) 2022-03-02
GB201905721D0 (en) 2019-06-05
CN113924298A (zh) 2022-01-11
IL287470A (en) 2021-12-01
AU2020263112A1 (en) 2021-12-16
GB2597228B (en) 2022-11-30
BR112021021284A2 (pt) 2022-01-18
WO2020216779A1 (en) 2020-10-29
IL287470B1 (en) 2024-02-01
EA202192905A1 (ru) 2022-02-17
JP2022530405A (ja) 2022-06-29
GB2597228A (en) 2022-01-19
KR20220012250A (ko) 2022-02-03

Similar Documents

Publication Publication Date Title
ZA202109179B (en) Compounds comprising n-methyl-2-pyridone, and pharmaceutically acceptable salts
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12018501920A1 (en) Bromodomain inhibitors
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
PH12016501750A1 (en) Human plasma kallikrein inhibitors
MX2015017215A (es) Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio.
EA033689B9 (ru) Ингибиторы g12c kras
MX2019003397A (es) Metodos para tratar trastornos mitocondriales y metabolicos.
PH12019501896A1 (en) Therapeutic dendrimers
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
NZ788133A (en) Cd73 inhibitors
ZA201808562B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MX2022003671A (es) Inhibidores de proteina cinasa i de interaccion con receptores para el tratamiento de enfermedades.
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX2018007511A (es) Compuestos de alquinil dihidroquinolina sulfonamida.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
NZ739679A (en) Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency
TR201900156T4 (tr) Tüberküloz ve ilgili hastalıkların tedavisi için kinolil hidrazonlar.